Spots Global Cancer Trial Database for brca mutation
Every month we try and update this database with for brca mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | NCT02042378 | Pancreatic Canc... Pancreatic Duct... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| A Training Set for the HRD Model in EOC | NCT04651933 | Epithelial Ovar... BRCA Mutation Loss of Heteroz... Prognosis Platinum Resist... Homologous Reco... | Homologous reco... | 18 Years - | Peking Union Medical College Hospital | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations | NCT05904730 | Breast Cancer Ovarian Cancer Breast Neoplasm... Ovarian Neoplas... BRCA Mutation HER2-positive B... HER2-negative B... HER-2 Protein O... | Axitinib | 18 Years - | Lynkcell Europe | |
| Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | NCT05485766 | Triple Negative... Triple Negative... Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation BRCA Mutation BRCA-Associated... | Pembrolizumab Paclitaxel Carboplatin Olaparib Definitive Surg... | 18 Years - | Okayama University | |
| Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion | NCT06033092 | BRCA Mutation PALB2 Gene Muta... Ductal Carcinom... Lobular Carcino... ATM Gene Mutati... CHEK2 Gene Muta... CDH1 Gene Mutat... RAD51C Gene Mut... RAD51D Gene Mut... | Tamoxifen 10 mg... Intermittent ca... Step counter De... | 18 Years - 70 Years | European Institute of Oncology | |
| Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer | NCT00496288 | Breast Cancer | Prophylactic ra... | 30 Years - 90 Years | Assaf-Harofeh Medical Center | |
| Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion | NCT06033092 | BRCA Mutation PALB2 Gene Muta... Ductal Carcinom... Lobular Carcino... ATM Gene Mutati... CHEK2 Gene Muta... CDH1 Gene Mutat... RAD51C Gene Mut... RAD51D Gene Mut... | Tamoxifen 10 mg... Intermittent ca... Step counter De... | 18 Years - 70 Years | European Institute of Oncology | |
| IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | NCT03551171 | Ovarian Cancer | ZL-2306 (nirapa... | 18 Years - | Zai Lab (Hong Kong), Ltd. | |
| Patient Empowerment by Group Medical Consultations | NCT01329068 | Breast Cancer BRCA Mutation | individual cons... group medical c... | 18 Years - | Radboud University Medical Center | |
| Frequency of Occult Breast Cancer After Prophylactic Mastectomy Among High-Penetrance Breast Cancer Gene Positives | NCT05771454 | Genetic Predisp... BRCA Mutation Breast Cancer Occult Cancer | Histopathologic... | 20 Years - 75 Years | Aga Khan University Hospital, Pakistan | |
| IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors | NCT06177171 | BRCA1 Mutation BRCA2 Mutation BRCA Mutation PALB2 Gene Muta... Checkpoint Kina... ATM Gene Mutati... | Olaparib ASTX727 | 18 Years - | University of California, San Francisco | |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) | NCT01945775 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib Physician's-Cho... | 18 Years - | Pfizer | |
| Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors | NCT03415659 | Advanced Solid ... HRD BRCA Mutation | HWH340 tablet | 18 Years - 70 Years | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | |
| Women At Risk: The High Risk Breast Cancer Program | NCT01034891 | Breast Cancer | 18 Years - | New York Presbyterian Hospital | ||
| Cancer Prevention in Women With a BRCA Mutation | NCT02225015 | BRCA1 Gene Muta... BRCA2 Gene Muta... Breast Cancer Ovarian Cancer | Follow-up Telep... | 35 Years - 70 Years | Women's College Hospital | |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) | NCT01945775 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib Physician's-Cho... | 18 Years - | Pfizer | |
| Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | NCT06380660 | Solid Tumor, Ad... BRCA1 Mutation BRCA2 Mutation Ovarian Cancer Breast Cancer Prostate Cancer | ACE-86225106 ta... | 18 Years - | Acerand Therapeutics Limited | |
| A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers | NCT02197000 | BRCA1 Gene Muta... BRCA2 Gene Muta... | DIM-Avail 100mg | 18 Years - 70 Years | Rabin Medical Center | |
| China Ovarian Cancer BRCA Testing Study | NCT03203993 | Ovarian Cancer | 18 Years - 130 Years | AstraZeneca | ||
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | NCT04672460 | Advanced Solid ... Solid Tumors Ovarian Cancer Breast Cancer Prostate Cancer NSCLC Pancreatic Canc... Colorectal Canc... | TALZENNA capsul... Talazoparib sof... Talazoparib sof... | 18 Years - 70 Years | Pfizer | |
| PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES | NCT05769517 | BRCA Mutation Ovarian Cancer Ultrasound Ther... | Germinal BRCA | - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| A Training Set for the HRD Model in EOC | NCT04651933 | Epithelial Ovar... BRCA Mutation Loss of Heteroz... Prognosis Platinum Resist... Homologous Reco... | Homologous reco... | 18 Years - | Peking Union Medical College Hospital | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | NCT00526617 | Non-hematologic... Metastatic Mela... Breast Cancer Ovarian Cancer Primary Periton... Fallopian Tube ... Hepatocellular ... | ABT-888 Temozolomide | 18 Years - | AbbVie | |
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage | NCT05554211 | Breast Cancer BRCA Mutation | Tranexamic acid Normal saline | 18 Years - 80 Years | Northwestern University | |
| IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA) | NCT04012229 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | BRCA mutation | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors | NCT03415659 | Advanced Solid ... HRD BRCA Mutation | HWH340 tablet | 18 Years - 70 Years | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | NCT06395519 | Advanced or Met... Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovar... BRCA2 Mutation ER+ Breast Canc... Castrate Resist... BRCA1 Mutation BRCA Mutation Endometrial Can... Colorectal Canc... Gastric Cancer | ETX-19477 | 18 Years - | 858 Therapeutics, Inc. | |
| A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | NCT02163694 | Metastatic Brea... | Veliparib Place... Veliparib Carboplatin Paclitaxel | 18 Years - | AbbVie | |
| A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) | NCT02034916 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib | 18 Years - | Pfizer | |
| A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) | NCT02034916 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
